Background: Typical atrioventricular accessory pathways (APs) are composed of
| INTRODUCTION
The typical accessory pathway (AP) is composed of myocardial cells spanning the fibrous atrioventricular (AV) junction. These cells provide electrical continuity between the atrial and ventricular myocardium at a site electrophysiologically distinct from the AV node and proximal His-Purkinje system. 1 Such connections have been described in the developing human heart, normally regressing by 20 weeks of gestation. It has been inferred that failure of these pathways to regress forms the substrate for APs. 2 Accessory pathways typically are capable of retrograde conduction, from ventricular to atrial myocardium, allowing them to participate in a macroreentrant tachycardia circuit that uses the atrial myocardium, AV node-His-Purkinje system, ventricular myocardium, and retrograde AP. This arrhythmia is known as orthodromic atrioventricular reciprocating tachycardia (OAVRT) and is a differential diagnosis for any regular, narrow QRS complex tachycardia that terminates in the face of second-degree AV block. 3 Rarely,
OAVRT can have a wide QRS complex, such as when there is preexisting or rate-dependent bundle branch block. 4, 5 Some APs also can conduct in the antegrade direction, electrically preexciting at least a portion of the ventricular myocardium with an atrial signal that bypasses the normal AV nodal-His-Purkinje system during sinus rhythm.
The degree of ventricular preexcitation (VPE) depends upon a number of factors, including the conduction properties of the antegrade AP and the antegrade AV node. 6, 7 Lidocaine is classified as an IB antiarrhythmic agent according to the Vaughan-Williams classification system. 8 It binds to and blocks open and inactivated fast sodium channels responsible for phase 0 (rapid depolarization) of the action potential in non-nodal cardiomyocytes.
Lidocaine exerts greater effects in depolarized (eg, ischemic) and rapidly driven tissues, making it a use-dependent antiarrhythmic agent. 9 Action potential duration usually is unaffected or shortened, perhaps because of block of the plateau sodium current. Lidocaine is highly effective for ventricular tachyarrhythmias, but largely ineffective for atrial tachyarrhythmias. A study in isolated atrial and ventricular myocytes, however,
showed that lidocaine's sodium current inhibition was essentially identical in these 2 cell types. 10 Thus, other mechanisms must be involved in the differential efficacy of lidocaine in ventricular versus atrial
tachyarrhythmias. 
| MATERIALS AND METHODS
A prospective, nonrandomized, single-arm clinical study was performed.
Dogs were included if they had a sustained narrow complex tachyarrhythmia strongly suspected to be OAVRT on baseline 12-lead ECG and after the owner's informed consent for treatment. The clinical tachyarrhythmia had to have regular R-R intervals, a short fixed RP 0 interval that was less than the P 0 R interval, immediate arrhythmia termination if second-degree AV block occurred, and be proven to be OAVRT at subsequent electrophysiologic study (EPS categorical data when expected cell counts were insufficient. All analyses were performed using commercially available statistical software (R Programming Language version 3.5.1, Boston, Massachusetts) and significance threshold was designated at P < .05.
F I G U R E 1 A, Six-lead ECG from an 8.3-year-old male Labrador Retriever with a narrow complex tachycardia, proven to be orthodromic atrioventricular reciprocating tachycardia at electrophysiologic study. Lidocaine was administered IV according to the study protocol. Twenty-seven dogs cardioverted with lidocaine, before adverse effects that precluded additional dosing occurred ( Figure 1 and Table 2 ). Termination occurred with a QRS complex that was not Table 3 ).
Adverse effects associated with lidocaine were encountered in 10 dogs (Table 2) . Five of these dogs converted to sinus rhythm at the dose at which adverse effects first developed, whereas the remaining 5 did not cardiovert, preventing them from reaching the maximal protocol lidocaine dose of 8 mg/kg. The median lidocaine dose reached in the 10 dogs with adverse effects was 6 mg/kg (IQR, 5.25-6 mg/kg).
Adverse effects were significantly associated with higher lidocaine dosages (P < .001, Table 3 Table 4 ). For those dogs that did cardiovert, lidocaine dose did not affect the likelihood of cardioversion between these 2 sites (P = .19; Table 5 ).
The fastest OAVRT cycle duration did not differ between dogs that cardioverted and those that did not (P = .4; Table 4 ), nor between dogs cardioverting at a low dose (2 mg/kg) and those requiring a higher lidocaine dose (>2 mg/kg) (P = .69; Table 5 ). No differences were identified between cardioverters and non-cardioverters with regard to age at presentation (P = .84), breed (Labrador versus nonLabrador, P = .64), sex (P = .29), or concealed versus manifest APs (P = 1.0; Table 4 ).
| DISCUSSION
Lidocaine generally is considered ineffective in treating narrow complex tachyarrhythmias. [17] [18] [19] In this series of 32 dogs with confirmed APs, however, lidocaine was successful in converting OAVRT to sinus Abbreviations: AP, atrioventricular accessory pathway; OAVRT, orthodromic atrioventricular reciprocating tachycardia.
effective or appropriate treatment for supraventricular tachyarrhythmias. 19 A small number of early single case studies demonstrated successful cardioversion of OAVRT with lidocaine administration. 21, 22 Other early studies in human patients suggested that lidocaine could be useful in slowing the ventricular response rate in preexcited atrial fibrillation by blocking antegrade conduction over the AP. 23, 24 One study demonstrated prolongation of the 1:1 atrial pacing cycle duration that resulted in loss of antegrade AP conduction (loss of VPE) after lidocaine administration. 24 This effect occurred in 4 of 6 patients evaluated, and suppression of antegrade AP conduction by the sodium channel blocking effects of lidocaine was postulated.
Subsequent studies in human patients, however, have not been favorable. Another study evaluated the effects of IV lidocaine on retrograde and antegrade AP conduction in human patients with WolffParkinson-White syndrome. 25 Lidocaine had no statistically significant effect on the AP's retrograde or antegrade effective refractory periods in the 9 (retrograde) and 11 (antegrade) patients who were tested.
Lidocaine also had no effect on the ease of OAVRT inducibility or on the tachycardia cycle duration in these patients. Another study found that lidocaine had inconsistent effects on the shortest and average R-R intervals during preexcited atrial fibrillation. 26 The average R-R interval decreased in 5 patients, increased in 2, and did not change in 1. The antegrade AP effective refractory period also was not prolonged in these patients with rapidly conducting antegrade APs. The medical community's general acceptance of the lack of therapeutic effect of lidocaine on supraventricular tachyarrhythmias is echoed in an article reviewing the pharmacologic treatment of narrow complex tachyarrhythmias in children. 27 Despite these reports in humans, lidocaine proved beneficial in acutely terminating OAVRT in our series of dogs. Lidocaine at therapeutic serum concentrations has no effect on the atrial effective refractory period. 28 In isolated atrial cardiomyocytes, lidocaine is effective in blocking the sodium current that is present. 10 The more depolarized resting membrane potential of atrial myocytes, however, results in less availability of inward sodium channels compared with ventricular myocytes. Thus, a smaller inward sodium current underlies the atrial action potential. The lack of a plateau phase in atrial myocytes also results in fewer inactivated sodium channels to be blocked by lidocaine and similar drugs. These findings can help explain why class IB agents have no clinically relevant electrophysiologic effects on atrial tissue, and there is general agreement that it is ineffective in the treatment of atrial arrhythmias. [28] [29] [30] [31] [32] In rare instances, atrial tachyarrhythmias do terminate with lidocaine. One study reported 8 human patients with an uncommon form of repetitive atrial tachycardia that showed progressive cycle duration prolongation during an atrial salvo, suppression as the sinus rate increased with mild exercise, and prolongation of salvoes with vagal stimulating maneuvers. 33 This form of atrial tachycardia, which appears to be vagally mediated, did respond to lidocaine administra- A potential limitation of our study is that lidocaine was not administered at the time of, but rather before, the EPS. We did not want lidocaine's effects on the AP to inhibit our ability to map and ablate it;
thus, we could not administer lidocaine during the EPS. Hence, one might argue that the narrow complex tachyarrhythmia seen before EPS could have had a different mechanism than OAVRT in these dogs.
We dispute that conclusion based on the following: (1) the ECG appearance of the narrow complex tachyarrhythmia in all of these dogs matched that of their electrophysiologically proven OAVRT during EPS the next day, with an identical, short, fixed RP 0 interval; (2) the narrow complex tachyarrhythmia terminated spontaneously immediately upon development of second-degree AV block, which would not be expected to occur with an atrial tachycardia; and (3) no narrow complex tachyarrhythmic mechanism other than OAVRT was identified at the time of EPS in this group of dogs.
In summary, our study supports the use of IV lidocaine for potential chemical cardioversion of a regular, narrow complex tachyarrhythmia in dogs. Successful cardioversion by lidocaine supports a tentative diagnosis of OAVRT as the narrow complex tachyarrhythmia's mechanism.
Failure to cardiovert does not definitively rule out OAVRT, particularly if adverse effects limit the maximal dose that can be administered.
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